Robert Kushner, Guest on Dr
A randomized, placebo-controlled Phase 2 trial (NCT02453711) of once-daily subcutaneous semaglutide (0.05, 0.1, 0.2, 0.3, or 0.4 mg following 4-weekly escalations) in subjects with obesity without T2D, showed mean weight losses of -6.0% (0.05 mg) to -13.8% (0.4 mg) with semaglutide vs -2.3% with placebo at week 52
TREATMENT SCHEDULE Microneedling: Every 34 weeks Topical Copper Peptides: Daily post-procedure, then as needed between sessions SKIN TYPES Suitable for all skin types
Calories and Macronutrient Balance : While GLP-1 agonists reduce appetite, patients must ensure they consume sufficient calories and protein to fuel workouts and stimulate muscle synthesis and prevent fatigue
Counter the damaging effects of NSAIDs on the stomach
No formal contraindications derived from human data exist because human safety trials have not been completed